ISOLATE LIVE EXFOLIATED COLONOCYTES FROM STOOL SAMPLES

从粪便样本中分离活的脱落结肠细胞

• 批准号: 2874244
• 负责人: RAMGOPAL NAIR
• 金额: $ 10万
• 依托单位: ATEK RESEARCH COMPANY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-04-01 至 2000-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2874244
• 关键词: biomarker; biomedical automation; biomedical equipment development; cell sorting; colon; colon neoplasms; exfoliative cytology; feces; flow cytometry; robotics; technology /technique development

This proposal is submitted in response to NIH Notice 98-086, entitled: "Development of High Throughput Assays for Exfolated Cells in Tumor Detection" The goal of this project is to automate a new technology for use in experimental cell biology and potentially as a screening tool for disease. The approach is based on the methods of Coprocytobiology (CCB), in which living exfoliated epithelial cells from the colonic mucosa are recovered from stools and then examined for micronutrient uptake, cell- surface markers, and disease biomarkers. In particular, the technique may prove useful for the detection of colorectal cancer well before the appearance of bleeding tumors. Possibly within the next decade this technique will become established as a fundamental tool for both gastrointestinal research and as a screening tool for clinical use. The CCB methodology is a highly developed but tedious manual process and is extremely time-consuming (approx. 1.4 samples/hr). This proposal presents an approach to automate this cell isolation technique, increasing throughput to 24 samples/hr. Our long-term goal is to produce a machine for no more than 20% the cost of an average flow cytometer. Additionally, a programmable version of this machine will allow researchers to test modified versions of CCB methodology. Industrial design and robotic automation methods will be employed in the construction of the machine. Major tasks will be component selection, mechanical and electrical design, and hardware-software system integration. Validation of results will be performed using microscopy and flow cytometry. PROPOSED COMMERCIAL APPLICATION: There are two main areas for commercial application of CCB automation: first in human cell biology research and second as a screening tool for preventative health care. The second application is dependent on the first, since CCB has been neglected by researchers, particularly by the gastroenterology community. A low cost automated device will make CCB application in research and human studies easier and attractive. If such studies prove CCB capable of sensitive and accurate screening tests for the early detection of colon cancer and other diseases, the market for an automated device will include most hospitals, HMOs, and clinical/pathology labs.

该提案是针对NIH通知98-086提交的，标题为“开发肿瘤检测中剥落细胞的高吞吐量测定”该项目的目的是自动化一种用于实验性细胞生物学的新技术，并有可能作为疾病的筛查工具。该方法基于核细胞生物学（CCB）的方法，其中从粪便中回收了从结肠粘膜中的生存的去角质上皮细胞，然后检查了微量营养素的摄取，细胞表面标记物和疾病生物标志物。 特别是，在出现出血肿瘤之前，该技术可能对检测结直肠癌很有用。可能在接下来的十年中，这项技术将成为胃肠道研究和临床使用的筛查工具的基本工具。 CCB方法是一种高度发达但乏味的手动过程，非常耗时（大约1.4个样本/小时）。 该建议提出了一种自动化此细胞隔离技术的方法，将吞吐量增加到24个样品/小时。 我们的长期目标是生产一台机器的成本不超过平均流式细胞仪的20％。 此外，该计算机的可编程版本将允许研究人员测试CCB方法的修改版本。工业设计和机器人自动化方法将用于机器的构建。主要任务将是组件选择，机械和电气设计以及硬件软件系统集成。结果将使用显微镜和流式细胞仪进行验证。拟议的商业应用：CCB自动化的商业应用有两个主要领域：首先是人类细胞生物学研究，其次是预防医疗保健的筛查工具。 第二个应用程序取决于第一个应用程序，因为CCB已被研究人员忽略，尤其是胃肠病学界。低成本的自动化设备将使CCB在研究和人类研究中的应用更容易，更具吸引力。如果此类研究证明CCB能够对结肠癌和其他疾病进行敏感和准确的筛查测试，则自动化设备的市场将包括大多数医院，HMO和临床/病理实验室。